You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kilickap S, Sezer A, Gümüş M, et al
600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0600